SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Y-mAbs Therapeutics, Inc. – ‘10-Q’ for 3/31/23

On:  Monday, 5/8/23, at 4:01pm ET   ·   For:  3/31/23   ·   Accession #:  1558370-23-8502   ·   File #:  1-38650

Previous ‘10-Q’:  ‘10-Q’ on 11/7/22 for 9/30/22   ·   Next:  ‘10-Q’ on 8/10/23 for 6/30/23   ·   Latest:  ‘10-Q’ on 5/7/24 for 3/31/24   ·   3 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/08/23  Y-mAbs Therapeutics, Inc.         10-Q        3/31/23   85:7.4M                                   Toppan Merrill Bridge/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.85M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     30K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     29K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     26K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     25K 
11: R1          Document and Entity Information                     HTML     77K 
12: R2          Consolidated Balance Sheets                         HTML    118K 
13: R3          Consolidated Balance Sheets (Parenthetical)         HTML     36K 
14: R4          Consolidated Statements of Net Loss and             HTML     87K 
                Comprehensive Loss                                               
15: R5          Consolidated Statements of Changes in               HTML     63K 
                Stockholders' Equity                                             
16: R6          Consolidated Statements of Cash Flows               HTML     82K 
17: R7          Organization and Description of Business            HTML     26K 
18: R8          Basis of Presentation                               HTML     31K 
19: R9          Summary of Significant Accounting Policies          HTML     85K 
20: R10         Product Revenue                                     HTML     56K 
21: R11         Net Loss Per Share                                  HTML     39K 
22: R12         Inventories                                         HTML     57K 
23: R13         Intangible Assets, Net                              HTML     27K 
24: R14         Accrued Liabilities                                 HTML     43K 
25: R15         License Agreements and Commitments                  HTML    154K 
26: R16         Stockholders' Equity                                HTML     34K 
27: R17         Share-Based Compensation                            HTML     93K 
28: R18         Related Party Transactions                          HTML     27K 
29: R19         Income Taxes                                        HTML     29K 
30: R20         Other Benefits                                      HTML     26K 
31: R21         Restructuring Charge                                HTML     28K 
32: R22         Summary of Significant Accounting Policies          HTML    111K 
                (Policies)                                                       
33: R23         Summary of Significant Accounting Policies          HTML     57K 
                (Tables)                                                         
34: R24         Product Revenue (Tables)                            HTML     48K 
35: R25         Net Loss Per Share (Tables)                         HTML     38K 
36: R26         Inventories (Tables)                                HTML     56K 
37: R27         Accrued Liabilities (Tables)                        HTML     42K 
38: R28         License Agreements and Commitments (Tables)         HTML    121K 
39: R29         Share-Based Compensation (Tables)                   HTML     83K 
40: R30         BASIS OF PRESENTATION - Accumulated deficit         HTML     26K 
                (Details)                                                        
41: R31         BASIS OF PRESENTATION - Cash and cash equivalents   HTML     26K 
                (Details)                                                        
42: R32         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     31K 
                Concentration of Credit Risk (Details)                           
43: R33         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair   HTML     41K 
                Value Measurement (Details)                                      
44: R34         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     25K 
                Operating Leases (Details)                                       
45: R35         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     24K 
                Revenue Recognition - Product revenue (Details)                  
46: R36         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     53K 
                Revenue Recognition - License revenue (Details)                  
47: R37         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     25K 
                Segment (Details)                                                
48: R38         PRODUCT REVENUE - Discounts and Allowances          HTML     67K 
                (Details)                                                        
49: R39         PRODUCT REVENUE - Concentrations (Details)          HTML     37K 
50: R40         PRODUCT REVENUE - Additional Information (Details)  HTML     35K 
51: R41         NET LOSS PER SHARE - Basic and diluted (Details)    HTML     46K 
52: R42         NET LOSS PER SHARE - Anti-dilutive securities       HTML     25K 
                (Details)                                                        
53: R43         Inventories (Details)                               HTML     40K 
54: R44         Intangible Assets, Net (Details)                    HTML     47K 
55: R45         Accrued Liabilities (Details)                       HTML     37K 
56: R46         LICENSE AGREEMENTS AND COMMITMENTS - MSK License    HTML     50K 
                (Details)                                                        
57: R47         LICENSE AGREEMENTS AND COMMITMENTS - LCD33 License  HTML     39K 
                (Details)                                                        
58: R48         LICENSE AGREEMENTS AND COMMITMENTS - MabVax/MSK     HTML     31K 
                License (Details)                                                
59: R49         LICENSE AGREEMENTS AND COMMITMENTS - SADA License   HTML     33K 
                Agreement (Details)                                              
60: R50         LICENSE AGREEMENTS AND COMMITMENTS - Summary of     HTML     55K 
                Significant Agreements and Commitments (Details)                 
61: R51         LICENSE AGREEMENTS AND COMMITMENTS - Other          HTML     42K 
                agreements (Details)                                             
62: R52         LICENSE AGREEMENTS AND COMMITMENTS - Lease          HTML     57K 
                agreements (Details)                                             
63: R53         LICENSE AGREEMENTS AND COMMITMENTS - Lease costs    HTML     32K 
                (Details)                                                        
64: R54         LICENSE AGREEMENTS AND COMMITMENTS - Lease          HTML     40K 
                maturities (Details)                                             
65: R55         LICENSE AGREEMENTS AND COMMITMENTS - Lease term     HTML     28K 
                and discount rate (Details)                                      
66: R56         LICENSE AGREEMENTS AND COMMITMENTS - Severance      HTML     32K 
                Related Benefits (Details)                                       
67: R57         LICENSE AGREEMENTS AND COMMITMENTS - Legal matters  HTML     26K 
                (Details)                                                        
68: R58         STOCKHOLDERS' EQUITY - Authorized, Common and       HTML     42K 
                Preferred Stock (Details)                                        
69: R59         STOCKHOLDERS' EQUITY - Stock grant agreements with  HTML     74K 
                non-employees (Details)                                          
70: R60         SHARE-BASED COMPENSATION - 2015 Plan (Details)      HTML     29K 
71: R61         SHARE-BASED COMPENSATION - 2018 Plan (Details)      HTML     49K 
72: R62         SHARE-BASED COMPENSATION - Stock-based              HTML     37K 
                compensation expense - Options (Details)                         
73: R63         SHARE-BASED COMPENSATION - Stock option activity    HTML     57K 
                (Details)                                                        
74: R64         SHARE-BASED COMPENSATION - Stock option grants      HTML     48K 
                (Details)                                                        
75: R65         SHARE-BASED COMPENSATION - Stock option             HTML     30K 
                unrecognized compensation (Details)                              
76: R66         SHARE-BASED COMPENSATION - Restricted Stock Unit    HTML     65K 
                Activity (Details)                                               
77: R67         Related Party Transactions (Details)                HTML     37K 
78: R68         INCOME TAXES - Loss before income taxes (Details)   HTML     34K 
79: R69         Other Benefits (Details)                            HTML     30K 
80: R70         Restructuring Charge (Details)                      HTML     45K 
83: XML         IDEA XML File -- Filing Summary                      XML    156K 
81: XML         XBRL Instance -- ymab-20230331x10q_htm               XML   1.47M 
82: EXCEL       IDEA Workbook of Financial Reports                  XLSX    144K 
 7: EX-101.CAL  XBRL Calculations -- ymab-20230331_cal               XML    129K 
 8: EX-101.DEF  XBRL Definitions -- ymab-20230331_def                XML    638K 
 9: EX-101.LAB  XBRL Labels -- ymab-20230331_lab                     XML   1.20M 
10: EX-101.PRE  XBRL Presentations -- ymab-20230331_pre              XML    994K 
 6: EX-101.SCH  XBRL Schema -- ymab-20230331                         XSD    197K 
84: JSON        XBRL Instance as JSON Data -- MetaLinks              395±   618K 
85: ZIP         XBRL Zipped Folder -- 0001558370-23-008502-xbrl      Zip    429K 




        
Filing Submission 0001558370-23-008502 – SGML Text

Original SGML Text submitted by:  Toppan Merrill Bridge/FA  (as Filing Agent) 

To view the SGML, please refresh
Refresh emoji
this page.


Top

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 10, 12:54:11.2pm ET